Beth Seidenberg
InvestorManaging Director at Westlake Village BioPartners · General Partner at Kleiner Perkins
Westlake Village, California, United States
Writes $100K – $5M checks
Midas 2020 · #54Midas 2019 · #59Midas 2018 · #62Midas 2016 · #98Midas 2015 · #91
About
Beth Seidenberg is a board‑certified physician and immunologist with rare drug‑development experience—helping develop Singulair at NIH and large pharma—who holds senior roles and chairs therapeutic boards shaping LA biotech ecosystem.
Invests in
AI & Machine LearningBiotechHealthtechMedical Devices
Experience
- Westlake Village BioPartnersCo-founding Managing Director at Westlake Village BioPartnerscurrent2018 — presentWestlake Village, California
- Kleiner PerkinsGeneral Partnercurrent2005 — presentMenlo Park, CA
- AmgenSenior Vice President2002 — 2005Thousand Oaks
- Bristol Myers SquibbSenior Vice President, Global Development2001 — 2002
- Bristol Myers SquibbSenior Vice President, Clinical Development & Life Cycle Management2000 — 2001
- Bristol Myers SquibbVice President, Clinical Immunology/Pulmonary/Dermatology2000
- MerckVice President, Pulmonary-Immunology1998 — 2000
- MerckExecutive Director1996 — 1998
- MerckSenior Director1993 — 1996
- MerckDirector, Clinical Pharmacology1991 — 1993
- MerckAssociate Director, Clinical Pharmacology1989 — 1991
Education
- Barnard CollegeBachelor of Science (BS)
- University of Miami Miller School of MedicineDoctor of Medicine (MD)
- The Johns Hopkins University School of MedicinePost Graduate Training
- National Institutes of HealthPost Graduate Training
Skills & more
From Beth's professional profile.
Same school
Also attended Barnard College28
+ 22 more
Also attended University of Miami Miller School of Medicine2
Also attended The Johns Hopkins University School of Medicine25
+ 19 more
Shared employers
Also worked at Westlake Village BioPartners9
+ 3 more
Also worked at Amgen53
+ 47 more
Also worked at Bristol Myers Squibb45
+ 39 more
Also worked at Merck90
+ 84 more
Deals · 17
Star Therapeutics LLCBoard seat
via Westlake Village BioPartners · filed Oct 2025 · $125M raise
Latigo BiotherapeuticsBoard seat
via Westlake Village BioPartners · filed Feb 2025 · $150M raise
Arsenal BiosciencesBoard seat
via Westlake Village BioPartners · filed Sep 2024 · $325.4M raise
Arsenal BiosciencesBoard seat
via Kleiner Perkins · filed Sep 2022 · $33M raise
Vera TherapeuticsBoard seat
via Kleiner Perkins · filed Feb 2021 · $70.7M raise
3-V BiosciencesBoard seat
via Westlake Village BioPartners · filed Jan 2021 · $80M raise
Tmunity TherapeuticsBoard seat
via Kleiner Perkins · filed Oct 2019 · $75M raise
FLX BioBoard seat
via Kleiner Perkins · filed Jun 2019 · $67.1M raise
KinsaBoard seat
via Kleiner Perkins · filed Apr 2018 · $14M raise
Breathe TechnologiesBoard seat
via Kleiner Perkins · filed Sep 2017 · $8.5M raise
Hixme Insurance SolutionsBoard seat
via Kleiner Perkins · filed Oct 2016 · $16M raise
Cell Design LabsBoard seat
via Kleiner Perkins · filed Jun 2016 · $22.9M raise
TesaroBoard seat
via Kleiner Perkins · filed Mar 2016 · $155M raise
LivongoBoard seat
via Kleiner Perkins · filed Apr 2015 · $20M raise
Flexus BiosciencesBoard seat
via Kleiner Perkins · filed Mar 2015 · $15.2M raise
AuxogynBoard seat
via Kleiner Perkins · filed Mar 2015 · $41M raise
3-V BiosciencesBoard seat
via Kleiner Perkins · filed Mar 2015 · $35M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Westlake Village BioPartners
Network11
Investors connected to Beth in public investor directories — a warm-intro map.










.png)















.png)



















